Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 6,059 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Phase 1 Interventional

A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

NCT05924243
View directory record Official record
Conditions
Parkinson Disease
Interventions
RO7486967, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

NCT04091425
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
TAK-925, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Serologic Strategies for Skilled Nursing Facilities

NCT05270980
View directory record Official record
Conditions
COVID-19
Interventions
Cohorting
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

NCT05078580
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 20, 2026, 5:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population

NCT06837246
View directory record Official record
Conditions
Cognition, Concentration, Attention, Focus
Interventions
Cognitive Nutritional Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Pharmavite LLC
Industry
Eligibility
25 Years to 65 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 20, 2026, 5:57 AM EDT
Not yet recruiting Phase 4 Interventional

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

NCT07369115
View directory record Official record
Conditions
Major Depressive Diorder, Early Life Trauma
Interventions
Lumateperone 42 mg, Placebo
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 20, 2026, 5:57 AM EDT
Withdrawn Phase 2 Interventional

Chinese Herbal Medicine for Gynecologic Patients

NCT06187376
View directory record Official record
Conditions
Dysmenorrhea
Interventions
Chinese Herbal Medicine (CHM) supplement, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 36 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 20, 2026, 5:57 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

NCT05856526
View directory record Official record
Conditions
Netherton Syndrome
Interventions
Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection, Placebo matching to spesolimab - solution for injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Rancho Santa Margarita, California • New Haven, Connecticut • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 3 Interventional

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

NCT05608343
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Difamilast, Placebo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

NCT03224325
View directory record Official record
Conditions
Healthy
Interventions
TAK-831 Tablet T2, Placebo, TAK-831 Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01378676
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Rhode Island Prescription and Illicit Drug Study

NCT04372238
View directory record Official record
Conditions
Opioid Overdose, Drug Overdose
Interventions
RAPIDS Intervention, Standard OEND
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

NCT03525548
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 20, 2026, 5:57 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

RBD Longitudinal as Prognostic for PD

NCT00817726
View directory record Official record
Conditions
Rapid Eye Movement Sleep Behavior Disorder
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
35 Years to 70 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

NCT01199289
View directory record Official record
Conditions
Asthma
Interventions
AMG 827, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

NCT02176655
View directory record Official record
Conditions
Delayed Alcohol Induced Headache
Interventions
VVD-101, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Mountain View, California • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

NCT00576589
View directory record Official record
Conditions
Obesity
Interventions
CE-326,597, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2010 · Synced Oct 20, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

NCT01275248
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Transcept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Beverly Hills, California • Imperial, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

NCT00672958
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
30
States / cities
Birmingham, Alabama • Cerritos, California • Encino, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 20, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

NCT02372799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 20, 2026, 5:57 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199
View directory record Official record
Conditions
Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations, NSCLC, Early Stage
Interventions
TAS6417, Zipalertinib Matching-placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
30
States / cities
Anchorage, Alaska • Duarte, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 5:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Normal Donor Sample Collection Study in Healthy Adults

NCT01318863
View directory record Official record
Conditions
Healthy Normal Volunteers
Interventions
Not listed
Lead sponsor
Astute Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
6
States / cities
Santa Ana, California • Las Vegas, Nevada • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 20, 2026, 5:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas

NCT01598116
View directory record Official record
Conditions
Hemangioma
Interventions
Urine collection and ultrasonography, Urine collection
Procedure
Lead sponsor
Gayle Gordillo
Other
Eligibility
4 Weeks to 5 Months
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 20, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

NCT01388933
View directory record Official record
Conditions
Crohn's Disease
Interventions
TU-100, Matching Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Little Rock, Arkansas • Corona, California • San Carlos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 20, 2026, 5:57 AM EDT